20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Solid Biosciences LLC (SLDB) operates in the BIOTECHNOLOGY industry and is headquartered in Charlestown, United States with about 121 employees. Its market capitalization is roughly $955 million. In the fiscal year ended 2025-12-31, SLDB reported $0M in revenue and ($174M) in net income.
Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy.
Interactive charts & full statements →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $8M | $14M | $3M | $0M | $0M | $0M | $0M | $0M |
| Gross Profit | — | ($2M) | ($2M) | ($3M) | $8M | $14M | ($4M) | ($3M) | ($2M) | $0M | $0M | $0M |
| Gross Margin % | — | — | — | — | 100.0% | 100.0% | -117.6% | — | — | — | — | — |
| Operating Income (EBIT) | ($212M) | ($179M) | ($130M) | ($104M) | ($106M) | ($72M) | ($86M) | ($119M) | ($76M) | ($55M) | ($26M) | ($7M) |
| Operating Margin % | — | — | — | — | -1315.2% | -530.5% | -2592.6% | — | — | — | — | — |
| Net Income | ($207M) | ($174M) | ($125M) | ($96M) | ($86M) | ($72M) | ($88M) | ($117M) | ($75M) | ($52M) | ($22M) | ($6M) |
| Net Margin % | — | — | — | — | -1062.3% | -530.0% | -2647.4% | — | — | — | — | — |
| EBITDA | ($205M) | ($173M) | ($122M) | ($93M) | ($97M) | ($69M) | ($84M) | ($116M) | ($74M) | ($54M) | ($26M) | ($7M) |
| Earnings Per Share (EPS) | $-1.91 | $-1.99 | $-3.06 | $-4.83 | $-10.10 | $-10.14 | $-25.50 | $-43.64 | $-33.72 | $-24.25 | $-16.80 | $-4.97 |
| Shares Outstanding (M) | 144M | 88M | 41M | 20M | 9M | 7M | 3M | 3M | 2M | 2M | 1M | 1M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | $0M | $3M | $0M |
| Gross Profit | — | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Gross Margin % | — | — | — | — | — | — | -15.6% | — |
| Operating Income (EBIT) | ($57M) | ($57M) | ($49M) | ($48M) | ($42M) | ($40M) | ($40M) | ($35M) |
| Operating Margin % | — | — | — | — | — | — | -1277.1% | — |
| Net Income | ($55M) | ($57M) | ($50M) | ($46M) | ($39M) | ($39M) | ($43M) | ($33M) |
| Net Margin % | — | — | — | — | — | — | -1363.5% | — |
| EBITDA | ($54M) | ($56M) | ($49M) | ($45M) | ($39M) | ($39M) | ($42M) | ($32M) |
| Earnings Per Share (EPS) | $-0.38 | $-0.52 | $-0.53 | $-0.48 | $-0.42 | $-0.59 | $-0.80 | $-0.79 |
| Shares Outstanding (M) | 144M | 110M | 95M | 94M | 94M | 66M | 54M | 41M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($187M) | ($156M) | ($100M) | ($94M) | ($98M) | ($78M) | ($57M) | ($93M) | ($70M) | ($43M) | ($20M) | ($4M) |
| Capital Expenditures (CapEx) | $1M | $1M | $1M | $2M | $3M | $1M | $1M | $4M | $8M | $2M | $0M | $0M |
| Free Cash Flow (FCF) | ($188M) | ($157M) | ($101M) | ($96M) | ($101M) | ($79M) | ($57M) | ($97M) | ($78M) | ($46M) | ($21M) | ($5M) |
| FCF Margin % | — | — | — | — | -1247.7% | -580.4% | -1724.1% | — | — | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($53M) | ($47M) | ($54M) | ($33M) | ($37M) | ($32M) | ($30M) | ($24M) |
| Capital Expenditures (CapEx) | $0M | $0M | $1M | $0M | $0M | $0M | $0M | $0M |
| Free Cash Flow (FCF) | ($53M) | ($47M) | ($54M) | ($34M) | ($38M) | ($32M) | ($30M) | ($24M) |
| FCF Margin % | — | — | — | — | — | — | -955.5% | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $421M | $233M | $189M | $165M | $260M | $232M | $171M | $103M | $140M | $76M | $41M | $56M |
| Cash & Cash Equivalents | $159M | $60M | $80M | $74M | $155M | $119M | $155M | $76M | $86M | $52M | $8M | $29M |
| Total Liabilities | $47M | $53M | $51M | $38M | $49M | $24M | $39M | $23M | $14M | $135M | $79M | $76M |
| Total Debt (Short + Long-Term) | $2M | $2M | $3M | $2M | $3M | $1M | $2M | $2M | $0M | $0M | $0M | $0M |
| Total Shareholders' Equity | $374M | $180M | $137M | $126M | $212M | $208M | $132M | $80M | $125M | ($59M) | ($84M) | ($68M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive SLDB viewer.
About TickerBase · Data methodology & sources · Privacy · Terms